AstraZeneca PLC (NASDAQ:AZN) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Conference Call Participants Zafar Aziz - Deutsche Bank Hello and welcome to the Deutsche Bank Depositary Receipts of Virtual Investor Conference. My name is Zafar Aziz from the Deutsche Bank team. I'm pleased to announce our next presentation will be from AstraZeneca from the U.K. Before I show our speaker, a few poi ...

AstraZeneca (AZN) announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma drug Fasenra (benralizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) indication.EGPA is a rare autoimmune disease that can cause damage to multiple organs and tissues. The AZN filing seeks marketing authorization for Fasenra as an add-on treatment for adult patients with relapsing or refractory ...

In my investing career, I have learned that quality is just as important of a consideration as valuation. The simultaneous presence of high-quality and a reasonable/discounted valuation usually bodes well for investment performance.Hi, my name is Kody. Aside from my four to five weekly articles here on Seeking Alpha, I am also a contributor to Sure Dividend, Dividend Kings, and iREIT on Alpha. I have been investing since September 2017 and interested in dividend investing since about 2009.Since July 2018, I ...

Key TakeawaysA breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.The company said it will present the new data to regulators who are weighing approval of the drug. Its shares fell Monday morning. British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "sta ...

The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.19%. Elsewhere, the Dow gained 0.09%, while the tech-heavy Nasdaq lost 0.36%.The pharmaceutical's shares have seen a decrease of 8.14% over the last month, not keeping up with the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.Market participants will be closely following the financi ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Astrazeneca (AZN) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Astrazeneca currently has an average brokerage recommendation ...

AstraZeneca (AZN) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with eosinophilic granulomatosis with polyangiitis (“EGPA”).EGPA is a rare autoimmune disease that can cause damage to multiple organs and tissues and is the second approved indication for Fasenra.Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA).Shares of AstraZe ...

AstraZeneca PLC (NASDAQ:AZN) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Sc ...

AstraZeneca PLC (NASDAQ:AZN) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Sc ...

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank. The analyst downgraded AZN to "sell" from "hold" and lowered its price target, pointing to the company's results from a lung cancer trial that showed its experimental precision drug did not improve overall survival.Coming into today, most analysts were bullish on AstraZeneca stock. Of the 14 in coverage, 11 rated it a "buy" or better, and the 12-month average target price of $90.89 is a ...